Company: BIAF
Filing Date: 2025-02-07
Form Type: 8-K
Source: 0001493152-25-005450
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-02-07
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item
3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On
February 7, 2025, bioAffinity Technologies, Inc. (the “ Company”) received written notice from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“ Nasdaq”) notifying the Company that for the preceding 30 consecutive business
days (December 23, 2024 through February 6, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00
(“ Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect
on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market
under the symbol “ BIAF.”

In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until August 6, 2025,
to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved without further action if the closing bid price
of the Company’s common stock is at or above $1.00 for a minimum of ten consecutive business days at any time during the 180-day
compliance period, in which case Nasdaq will notify the Company if it determines it is in compliance and the matter will be closed; however
Nasdaq may require the closing bid price to equal or to exceed the $1.00 minimum bid price requirement for more than 10 consecutive business
days before determining that a company complies.

If,
however, the Company does not achieve compliance with the Minimum Bid Price Requirement by August 6, 2025, the Company may be eligible
for additional time to comply. In order to be eligible for such additional time, the Company will be required to meet the continued listing
requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the
exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of its intention to cure the deficiency during the
second compliance period.

The
Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the
Nasdaq listing requirements.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of